Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4602-4608

  Von Der Maase, Hans ^a   Sengelov, Lisa ^a   Roberts, James T ^a   Ricci, Sergio ^a   Dogliotti, Luigi ^a   Oliver, T ^a   Moore, Malcolm J ^a   Zimmermann, Annamaria ^a   Arning, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; M VAC PROTOCOL; M-VAC PROTOCOL;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 23044501890     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.757     Document Type: Article

References (16)

1. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
3. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
4. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
5. von der Maase H: Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 3:11-19, 2003
6. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
7. Robinson P, von der Maase H, Bhalla S, et al: Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Rev Pharmacoeconomics Outcomes Res 4:27-38, 2004
8. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
9. Stadler WM, Hayden A, von der Maase H, et al: Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7:153-157, 2002
10. von der Maase H, Andersen L, Crino L, et al: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 10:1461-1465, 1999
11. Moore MJ, Winquist EW, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876-2881, 1999
12. Kaufman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927, 2000
13. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999
14. Bajorin D: The phase III candidate: Can we improve the science of selection? J Clin Oncol 22:211-213, 2004
15. Sengelov L, Kamby C, von der Maase H: Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 39:634-642, 2001
16. von der Maase H, Sengelov L: Chemotherapy in locally advanced and metastatic bladder cancer. Am J Cancer 4:1-13, 2005